The company, formerly known as Zhejiang Asia Pacific Pharmaceutical Factory, was founded in 1989, completed the shareholding system reform in December 2001, and officially listed on the Shenzhen Stock Exchange on March 16, 2010. The company's main business is pharmaceutical manufacturing, including R&D, production and sales of chemical agents. The main customers are pharmaceutical businesses, distribution companies and medical institutions. The company's main products are amoxicillin clavulanate potassium dispersible tablets, azithromycin dispersible tablets, roxithromycin capsules, injectable cefazoxime sodium, injectable pantoprazole sodium, injectable omeprazole enteric capsules, lansoprazole enteric capsules, ribavirin for injections, acyclovir for injections, cardiovascular drugs, antipyretic analgesics, roxithromycin, azithromycin, esomeprazole sodium Cycline, entecavir. Corporate honors: Enterprise Credit Rating AAA; Shaoxing County Advanced Tax Payment Unit; Shaoxing County Advanced Tax Payment Unit; Shaoxing County Family Planning Advanced Unit; Shaoxing County Enterprise Credit Rating AAA, etc.
No Data